Point-of-care diagnostics and therapeutics have the potential to radically change and improve the way disease and illness are detected and managed. This can be achieved by empowering the patient with rapid, real time information. Point of care testing also has the potential to alleviate some of the burden on crippled health care systems worldwide. Furthermore, personalised point-of-care testing can give more tailored and specific feedback to the end user. In this body of work, a novel single cell analysis system for antibody discovery and an integrated personalised point-ofcare platform is presented. In the first instance key challenges in the development of a novel single cell analysis antibody selection platform were addressed. This Direct Clone Analysis and Selection (DiCAST) Technology incorporates a highly ordered array of glass microcapillaries of 20 µm diameter. The first key challenge was to identify a single target micro-capillary of interest, containing the single antibody secreting cell of interest, among ≈ 1,000,000 other identical capillaries and cells. To achieve this, the ability to map assay patterns from the micro-capillary array to the master array containing the target cell was critical. Similar to where X marks the spot on a treasure map, micro-capillaries in a predefined pattern and orientation were blocked permanently using photolithography providing a reference stamp for alignment. These blocked capillaries provided a reference point upon the array, giving both spatial reference and orientation, allowing the cell recovery hardware to locate the micro-capillaries required to be evacuated. Following the successful mapping of the array of micro capillaries the recovery of the contents of the micro-capillaries proved elusive. Here a system for the recovery of single cells from a micro-capillary was developed. Initially investigated was a method whereby a micro-jet of air, passed through a nozzle equal in diameter to the micro-capillary, for the removal of its contents. With limited success it was demonstrated that, while single micro-capillaries could be interrogated and the contents removed, the successful and controlled recovery of the contents was inconclusive. Subsequently, a liquid recovery system was investigated. By coupling both ends of the micro-capillary with a glass capillary of similar internal diameter, and by flowing a buffer solution through the capillary, recovery of the contents of a single micro-capillary was demonstrated. In a second body of work, a method for cellular fraction extraction using an active trapping (CLEAR) approach was developed. CLEAR separates plasma from a whole blood sample in <10 min by removing the red and white blood cells to give improved signal to noise ratio during a subsequent fluorescence measurement of the on chip assay. Designed for point-of-care applications, CLEAR requires no external actuation relying on degas driven flow, together with cell gravitational sedimentation in a trench to separate the sample, removing the need for pumps, tubing, extra power sources etc. CLEAR removes the likelihood of cell re-suspension by actively sequestering those cells to a separate reservoir on chip. As a result, CLEAR could be used to analyse the cellular constituents post separation, to screen xii for e.g. cell health or cell counting. The CLEAR concept was demonstrated using a fluorescence-based sandwich assay for the cardiac marker C-reactive protein (CRP). The research presented in this thesis describes the initial development of two key biomedical platforms that if combined has the potential for improved point of care testing. Using the research described herein as a corner stone for future follow on development and validation, it is envisaged that best in class antibodies selected using the novel DiCAST antibody discovery platform could be applied in a fluorescence-based assay on a whole blood sample using the CLEAR microfluidic chip platform for improved cardiac diagnosis at the point of patient need.